Paul Clancy, CFO of Biogen (NASDAQ: BIIB) for the last 10 years, is moving to Alexion Pharmaceuticals (NASDAQ: ALXN) to become the top financial executive of the New Haven, CT, drug developer. Before joining Cambridge, MA-based Biogen, Clancy held various executive positions at PepsiCo (NYSE: PEP).
Alexion says Clancy will start at the company on July 10. He will succeed CFO Dave Anderson, who will continue in his role until July 31. To help with Clancy’s transition, Anderson will remain with the company through August as a senior advisor to Alexion’s CEO.